⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CNTX News
Context Therapeutics Inc. Common Stock
Form 8-K
sec.gov
CNTX
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
globenewswire.com
CNTX
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CNTX
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
globenewswire.com
CNTX
Form 8-K
sec.gov
CNTX
BCAB
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
globenewswire.com
CNTX
BCAB
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
globenewswire.com
CNTX
Form 8-K
sec.gov
CNTX
Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary
businesswire.com
NEOG
CNTX
Form 8-K
sec.gov
CNTX